JP2023522307A5 - - Google Patents

Info

Publication number
JP2023522307A5
JP2023522307A5 JP2022559709A JP2022559709A JP2023522307A5 JP 2023522307 A5 JP2023522307 A5 JP 2023522307A5 JP 2022559709 A JP2022559709 A JP 2022559709A JP 2022559709 A JP2022559709 A JP 2022559709A JP 2023522307 A5 JP2023522307 A5 JP 2023522307A5
Authority
JP
Japan
Prior art keywords
disorder
schizophrenia
group
compound
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022559709A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522307A (ja
JP7617134B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/058099 external-priority patent/WO2021198149A1/en
Publication of JP2023522307A publication Critical patent/JP2023522307A/ja
Publication of JP2023522307A5 publication Critical patent/JP2023522307A5/ja
Application granted granted Critical
Publication of JP7617134B2 publication Critical patent/JP7617134B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022559709A 2020-03-30 2021-03-29 Gpr52アゴニスト活性を有する置換3-フェノキシアゼチジン-1-イル-ピラジン Active JP7617134B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063001640P 2020-03-30 2020-03-30
US63/001,640 2020-03-30
PCT/EP2021/058099 WO2021198149A1 (en) 2020-03-30 2021-03-29 Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity

Publications (3)

Publication Number Publication Date
JP2023522307A JP2023522307A (ja) 2023-05-30
JP2023522307A5 true JP2023522307A5 (cg-RX-API-DMAC7.html) 2024-05-23
JP7617134B2 JP7617134B2 (ja) 2025-01-17

Family

ID=75362607

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022559709A Active JP7617134B2 (ja) 2020-03-30 2021-03-29 Gpr52アゴニスト活性を有する置換3-フェノキシアゼチジン-1-イル-ピラジン

Country Status (20)

Country Link
US (1) US11780827B2 (cg-RX-API-DMAC7.html)
EP (1) EP4126850B1 (cg-RX-API-DMAC7.html)
JP (1) JP7617134B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220161454A (cg-RX-API-DMAC7.html)
CN (1) CN115697997B (cg-RX-API-DMAC7.html)
AR (1) AR121675A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021250303A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022018996A2 (cg-RX-API-DMAC7.html)
CA (1) CA3176265A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022014886A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220554A (cg-RX-API-DMAC7.html)
DO (1) DOP2022000203A (cg-RX-API-DMAC7.html)
EC (1) ECSP22080683A (cg-RX-API-DMAC7.html)
IL (1) IL296823A (cg-RX-API-DMAC7.html)
JO (1) JOP20220235A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022012067A (cg-RX-API-DMAC7.html)
PE (1) PE20221918A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552553A1 (cg-RX-API-DMAC7.html)
TW (1) TW202204343A (cg-RX-API-DMAC7.html)
WO (1) WO2021198149A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4139284A1 (en) 2020-04-22 2023-03-01 Neurocrine Biosciences, Inc. Gpr52 modulators and methods of use
WO2023041432A1 (en) 2021-09-14 2023-03-23 Boehringer Ingelheim International Gmbh 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament
CN119143731B (zh) * 2024-09-13 2025-08-26 中国海洋大学 一种吡嗪酰胺类化合物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2361149A1 (en) 1998-12-23 2000-07-06 Eli Lilly And Company Aromatic amides
JPWO2009107391A1 (ja) 2008-02-27 2011-06-30 武田薬品工業株式会社 6員芳香環含有化合物
GB0808668D0 (en) * 2008-05-13 2008-06-18 Univ Aberdeen Materials and methods relating to a G-protein coupled receptor
EP2298731A4 (en) 2008-06-25 2011-09-21 Takeda Pharmaceutical AMIDE COMPOUND
EP2518054A1 (en) * 2009-12-24 2012-10-31 Takeda Pharmaceutical Company Limited Amide compound
EP2530078A1 (en) 2010-01-27 2012-12-05 Takeda Pharmaceutical Company Limited Thiazole derivative
WO2011145735A1 (ja) 2010-05-21 2011-11-24 武田薬品工業株式会社 チアゾール誘導体
WO2012020738A1 (ja) 2010-08-09 2012-02-16 武田薬品工業株式会社 複素環化合物およびその用途
WO2012076063A1 (en) 2010-12-10 2012-06-14 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
MX373876B (es) * 2015-04-29 2020-03-26 Arena Pharm Inc 1-heteroaril-indolin-4-carboxamidas como moduladores de gpr52 útiles para el tratamiento o prevención de trastornos relacionados a las mismas.
AU2016324317A1 (en) * 2015-09-17 2018-03-08 Coda Biotherapeutics, Inc. Compositions and methods for treating neurological disorders

Similar Documents

Publication Publication Date Title
JP2004534816A5 (cg-RX-API-DMAC7.html)
JP2020183410A5 (cg-RX-API-DMAC7.html)
TWI657078B (zh) 作爲單胺氧化酶(mao)抑制劑之經取代之萘啶及喹啉化合物
IL298871A (en) The composition consisting of the benzoate salt of 5-methoxy-N,N-dimethyltryptamine
RU2012140148A (ru) (2s,3r)-n-(2-((3-пиридинил)метил)-1-азабицикло[2.2.2]окт-3-ил)бензофуран-2-карбоксамид, новые солевые формы и способы их применения
JP2009524676A5 (cg-RX-API-DMAC7.html)
ES2971230T3 (es) Compuestos inhibidores de VMAT2 y composiciones de los mismos
JP2009534368A5 (cg-RX-API-DMAC7.html)
JP2018507877A5 (cg-RX-API-DMAC7.html)
FI3856182T3 (fi) Koostumuksia ja menetelmiä muskariinireseptorin aktivaation lievittämien häiriöiden hoitamiseksi
JP2010529081A5 (cg-RX-API-DMAC7.html)
JP2018519351A5 (cg-RX-API-DMAC7.html)
JP2007516193A5 (cg-RX-API-DMAC7.html)
JP2011524850A5 (cg-RX-API-DMAC7.html)
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害(adhd)の治療方法
JP2017528515A5 (cg-RX-API-DMAC7.html)
JP2007532637A5 (cg-RX-API-DMAC7.html)
JP2022539152A5 (cg-RX-API-DMAC7.html)
AU2014364565B2 (en) [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis
WO2011097946A1 (zh) 含有并环稠合双环的噁唑烷酮化合物及其制备和应用
JP2003513071A5 (cg-RX-API-DMAC7.html)
US20180244623A1 (en) N-methyl-D-aspartate Receptor (NMDAR) Potentiators, Pharmaceutical Compositions, And Uses Related Thereto
JP2022180531A5 (cg-RX-API-DMAC7.html)
RU2004117211A (ru) Способы лечения депресии и других рассстройств цнс с использованием энантиомерно обогащшенных десметил-и дидесметилметаболитов циталопрама
US20080096867A1 (en) Imidazo[1,2-A] Pyridine Anxiolytics